– USA, MA – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Dr. Mark Velleca, M.D., Ph.D. to its Board of Directors, bringing over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as CEO of G1 Therapeutics.
“I am delighted to welcome Mark to the Black Diamond Board of Directors,” said Board Chairman, Robert Ingram. “Mark brings substantial experience in a range of leadership roles in the life sciences sector, and his perspective will be integral as Black Diamond executes on its vision of developing novel precision medicine therapies for genetically defined cancers.”
“We are pleased to welcome Mark to our Board, as his financial, regulatory, and medical expertise will complement our existing credentialed group of directors,” said CEO, Dr. David Epstein. “Mark’s experience in shepherding drugs from discovery through commercialization will enable him to provide valuable insights as we advance our deep pipeline of targeted oncology therapies.”
About
Dr. Velleca was most recently CEO of G1 Therapeutics, where he grew the company from Series A through IPO and led the development of its first therapy from preclinical to FDA approval. Previously, he served as EVP at the Leukemia & Lymphoma Society. Prior to LLS, Dr. Velleca was co-founder and SVP of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. After Gilead Sciences acquired CGI, he served as a Senior Advisor to Gilead in R&D Strategy and Corporate Development. Earlier in his career, Dr. Velleca was an attending physician at the Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Currently, Dr. Velleca is a Senior Advisor and board member at G1 Therapeutics, board member at IMMvention Therapeutix, board chair at Turbine AI, and a Venture Partner at Hatteras Venture Partners.
“I am delighted to join Black Diamond Therapeutics’ Board of Directors, as their novel approach to precision medicine has the potential to transform the treatment landscape of targeted therapies. Oncology continues to be an area of immense unmet need, and the MAP platform offers a unique opportunity to address these challenges,” said Dr. Velleca. “I look forward to working with the team to contribute to Black Diamond’s future growth and success.”
He earned an M.D. and Ph.D. from Washington University in St. Louis and a B.S. from Yale University.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform and drug discovery engine, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by Dr. David Epstein, Ph.D., and Dr. Elizabeth Buck, Ph.D.
For more information: https://www.blackdiamondtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.